Author
Listed:
- Xiang Yu
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
- Yanfeng Dai
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
- Yifan Zhao
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
- Shuhong Qi
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
- Lei Liu
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
- Lisen Lu
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
- Qingming Luo
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
- Zhihong Zhang
(Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Huazhong University of Science and Technology)
Abstract
Targeted delivery of a nanovaccine loaded with a tumor antigen and adjuvant to the lymph nodes (LNs) is an attractive approach for improving cancer immunotherapy outcomes. However, the application of this technique is restricted by the paucity of suitable tumor-associated antigens (TAAs) and the sophisticated technology required to identify tumor neoantigens. Here, we demonstrate that a self-assembling melittin-lipid nanoparticle (α-melittin-NP) that is not loaded with extra tumor antigens promotes whole tumor antigen release in situ and results in the activation of antigen-presenting cells (APCs) in LNs. Compared with free melittin, α-melittin-NPs markedly enhance LN accumulation and activation of APCs, leading to a 3.6-fold increase in antigen-specific CD8+ T cell responses. Furthermore, in a bilateral flank B16F10 tumor model, primary and distant tumor growth are significantly inhibited by α-melittin-NPs, with an inhibition rate of 95% and 92%, respectively. Thus, α-melittin-NPs induce a systemic anti-tumor response serving as an effective LN-targeted whole-cell nanovaccine.
Suggested Citation
Xiang Yu & Yanfeng Dai & Yifan Zhao & Shuhong Qi & Lei Liu & Lisen Lu & Qingming Luo & Zhihong Zhang, 2020.
"Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response,"
Nature Communications, Nature, vol. 11(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-14906-9
DOI: 10.1038/s41467-020-14906-9
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Yannan Yang & Shiwei Chen & Min Zhang & Yiru Shi & Jiangqi Luo & Yiming Huang & Zhengying Gu & Wenli Hu & Ye Zhang & Xiao He & Chengzhong Yu, 2024.
"Mesoporous nanoperforators as membranolytic agents via nano- and molecular-scale multi-patterning,"
Nature Communications, Nature, vol. 15(1), pages 1-15, December.
- Wan-Ru Zhuang & Yunfeng Wang & Weidong Nie & Yao Lei & Chao Liang & Jiaqi He & Liping Zuo & Li-Li Huang & Hai-Yan Xie, 2023.
"Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity,"
Nature Communications, Nature, vol. 14(1), pages 1-15, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-14906-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.